Longeveron Finalizes 1-for-10 Reverse Split Effective August 26
LGVN sits 58% above its 52-week low of $0.475 on elevated volume (2.1× avg).
Summary
Longeveron finalized a 1-for-10 reverse stock split effective August 26, 2026, to regain Nasdaq compliance. The split reduces outstanding Class A shares from ~30.4M to ~3.0M.
Key Events · Corporate Governance and Compliance · LGVN
-
Reverse Split Finalized
Board approved a 1-for-10 reverse stock split effective 11:59 p.m. ET on August 26, 2026. Every 10 shares of Class A and Class B common stock will convert into 1 share.
-
Nasdaq Compliance Goal
The split is intended to raise the per-share price above the $1.00 minimum bid requirement. At today's $0.75 price, the split-adjusted price would be approximately $7.50.
-
Share Count Reduction
Outstanding Class A shares will drop from ~30,432,974 to ~3,043,298, and Class B from ~1,449,005 to ~144,901. Authorized shares and par value remain unchanged.
-
Trading Details
Class A common stock will begin trading on a split-adjusted basis on August 27, 2026, under new CUSIP 54303L 302 and the existing ticker LGVN.
Analysis · LGVN · Life Sciences
Longeveron has locked in the final terms of its reverse stock split: a 1-for-10 ratio effective at 11:59 p.m. ET on August 26, 2026. The move is designed to lift the share price above Nasdaq's $1.00 minimum bid requirement, addressing a delisting risk that has been hanging over the company. With the stock trading at $0.75 today, the split would theoretically push the price to around $7.50 per share, giving the company breathing room to regain compliance. However, the reverse split does not change the underlying fundamentals — the company still faces a going-concern warning and a cash runway only into Q4 2026. The split also reduces the outstanding share count from roughly 30.4 million Class A shares to about 3.0 million, which could increase volatility and make the stock more susceptible to large percentage swings.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2796 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LGVN was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.7M. The 52-week trading range was $0.48 to $1.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.